Bellicum Pharmaceuticals Gets $55M For Immunotherapy Efforts

Houston-based Bellicum Pharmaceuticals announced this morning that it has raised $55M in a Series C funding, to go towards development of its cellular immunotherapy products. According to Bellicum, the funding came from RA Capital Management, LLC, Perceptive Advisors, LLC, Jennison Associates LLC (on behalf of certain clients), Sabby Capital, LLC, Ridgeback Capital Management, venBio Select, Redmile Group, LLC, AJU IB Investment and others. The funding also included prior investors AVG Ventures and Remeditex Ventures. The company said it has now raised $107M in funding. The new funds go towards its clinical evaluation efforts. The company said its placement agent in the effort was Jeffries LLC. More information »